Scotiabank raises JNJ target to $305 from $265Scotiabank 上调目标价 强生 (JNJ)：$265 → $305
Target Price Revision Details
Scotiabank raised its per-share price target for Johnson & Johnson (JNJ) from $265 to $305 on July 16, 2026, a 15.1% upward adjustment, for the $594.6B market-cap healthcare sector leader. As of the revision date, JNJ’s current share price was $249.47, with a daily gain of approximately 0.99%. This update only modifies the price target without adjusting the firm’s investment rating on JNJ, representing a standalone valuation expectation shift rather than a full rating revision.
The revision aligns with JNJ’s just-released second-quarter 2026 earnings, disclosed via a July 15, 2026 SEC 8-K filing: the company posted adjusted EPS of $2.9, beating consensus estimates of $2.84, and total revenue of $25.31B, exceeding the $25.02B consensus forecast, alongside an upwardly revised full-year 2026 outlook.
Follow-up Markers
This signal reflects only Scotiabank’s internal valuation model, and does not constitute an investment recommendation of any kind; it does not capture concurrent rating or target price changes from other Wall Street firms; it does not guarantee near-term or long-term share price movement for JNJ.
目标价调整详情
丰业银行（Scotiabank）于2026年7月16日宣布将强生（JNJ）的每股目标价从265美元上调至305美元，上调幅度达15.1%，涉及标的当前市值约5946亿美元，为全球医疗保健行业龙头企业。截至调整当日，强生当前股价为249.47美元，当日涨幅约0.99%。此次调整仅涉及目标价上调，未同步调整投资评级，属于单一估值预期的修正，而非全面评级变更。
该调整与强生前一日发布的第二季度财报直接相关：2026年7月15日强生提交的SEC 8-K文件显示，其二季度每股收益达2.9美元，超出市场一致预期的2.84美元；总营收为253.1亿美元，高于市场预期的250.21亿美元，同时公司同步上调了2026年全年业绩指引。
后续关注
该信号仅代表丰业银行的独立估值判断，不构成任何投资建议；未覆盖其他投行同期的评级或目标价调整动作；无法直接预测强生股价的短期或长期走势。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。